Horizon Therapeutics (DB:HPR) - Prezzo delle azioni, notizie e analisi

HPR Panoramica delle azioni

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Maggiori dettagli

HPR analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	4/6
Prestazioni passate	1/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Negoziato a 55.8% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 24.94% all'anno

Analisi del rischio

Grandi elementi una tantum che incidono sui risultati finanziari

I margini di profitto (12%) sono inferiori rispetto allo scorso anno (20.1%)

Horizon Therapeutics Public Limited Company Concorrenti

Biotest

XTRA:BIO3

€1.4b

Formycon

XTRA:FYB

€827.2m

Sartorius

XTRA:SRT3

€13.4b

Merck KGaA

XTRA:MRK

€61.6b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Horizon Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$110.20
Massimo di 52 settimane	US$110.80
Minimo di 52 settimane	US$61.68
Beta	1.01
1Variazione di 1 mese	3.38%
Variazione a 3 mesi	17.86%
Variazione di 1 anno	67.30%
3Variazione a 3 anni	54.28%
Variazione a 5 anni	601.91%
Variazione dall'IPO	1,783.76%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	HPR	DE Biotechs	DE Mercato
7D	-0.2%	-0.7%	0.2%
1Y	67.3%	-17.2%	8.5%

Ritorno vs Industria: HPR ha superato il German Biotechs che ha restituito -17.2 % nell'ultimo anno.

Rendimento vs Mercato: HPR ha superato il mercato German che ha restituito 8.5 % nell'ultimo anno.

Volatilità dei prezzi

Is HPR's price volatile compared to industry and market?
HPR volatility
HPR Average Weekly Movement	2.8%
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.3%

Prezzo delle azioni stabile: HPR non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 3% ) di HPR è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2005	2,190	Tim Walbert	www.horizontherapeutics.com

Horizon Therapeutics Public Limited Company Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Horizon Therapeutics con la sua capitalizzazione di mercato?
HPR statistiche fondamentali
Capitalizzazione di mercato	€25.30b
Guadagni(TTM)	€416.06m
Ricavi(TTM)	€3.46b

60.8x

Rapporto P/E

7.3x

Rapporto P/S

HPR è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
HPR Conto economico (TTM)
Ricavi	US$3.64b
Costo del fatturato	US$824.98m
Profitto lordo	US$2.82b
Altre spese	US$2.38b
Guadagni	US$438.00m

Ultimi guadagni dichiarati

Jun 30, 2023

Prossima data di guadagno

n/a

Utile per azione (EPS)	1.91
Margine lordo	77.36%
Margine di profitto netto	12.02%
Rapporto debito/patrimonio netto	48.2%

Come si è comportato HPR nel lungo periodo?

Vedi performance storica e confronto

HPR Panoramica delle azioni

Premi

Analisi del rischio

Horizon Therapeutics Public Limited Company Concorrenti

XTRA:BIO3

€1.4b

XTRA:FYB

€827.2m

XTRA:SRT3

€13.4b

XTRA:MRK

€61.6b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Recent updates

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023

Horizon Therapeutics plc Announces New Analysis of MRI Findings Shows UPLIZNA®? (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc Announces Tepezza® (Teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (Optic-J) in Japan

Horizon Therapeutics plc Announces Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

Horizon Therapeutics plc Announces the Publication of New Analysis from the N-MOmentum Clinical Trial of UPLIZNA Demonstrating the Utility of A Robust Assay Process

Horizon Therapeutics plc Announces Data from the Teprotumumab Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease

Horizon Therapeutics plc Announces the Publication of New Data from the Phase 3 N-MOmentum Pivotal Trial of UPLIZNA

Horizon Therapeutics plc Announces Presentations At the 2023 Eular European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’S Syndrome

Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Amgen Inc. (NasdaqGS:AMGN) entered into a transaction agreement to acquire Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) for $27.1 billion.

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Investor sentiment improved over the past week

Insufficient new directors

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (Optic-J) in Japan Evaluating Tepezza® for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Investor sentiment improved over the past week

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Horizon Therapeutics Public Limited Company Announces Data Support the Use of KRYSTEXXA (Pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People with Mild-To-Moderate Chronic Kidney Disease

Third quarter 2022 earnings released: EPS: US$0.59 (vs US$1.44 in 3Q 2021)

Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Horizon Therapeutics plc Announces New Data from Two Analyses of the Uplizna Phase 3 Pivotal Trial Presented At the 38(Th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims 2022), Oct. 26-28 in Amsterdam

Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (Teprotumumab-Trbw) in Adults with Chronic/Low Clinical Activity Score (Cas) Thyroid Eye Disease (Ted)

Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint

Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) announces an Equity Buyback for $500 million worth of its shares.

Second quarter 2022 earnings released: EPS: US$0.27 (vs US$0.70 in 2Q 2021)

Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022

FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022

Horizon Therapeutics Public Limited Company Announces New Analysis Finds UPLIZNA (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Horizon Therapeutics plc Submits Regulatory Filing for Uplizna® (Inebilizumab) in Brazil

Horizon Therapeutics Public Limited Company Announces Results of A New Analysis Examining Rates of Hyperglycemia Among Patients Treated with TEPEZZA for TED Compare to Placebo in the Phase 2 and OPTIC Phase 3 Clinical Trials

Horizon Therapeutics plc Announces Analysis from the Phase 3 N-Momentum Study Demonstrates the Effectiveness of Uplizna(R) (Inebilizumab-Cdon) Among Neuromyelitis Optica Spectrum Disorder Patients with Genetic Variations

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab (Hzn-7734) for the Treatment of Alopecia Areata

First quarter 2022 earnings released: EPS: US$0.89 (vs US$0.55 loss in 1Q 2021)

Horizon Therapeutics Public Limited Company Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Receives European Commission Approval of Uplizna (Inebilizumab) for the Treatment of Adults with Neuromyelitis Optica Spectrum Disorder

Insufficient new directors

Horizon Therapeutics Public Limited Company to Report Q1, 2022 Results on May 04, 2022

Horizon Therapeutics plc Announces Presentation of A Post-Hoc Analysis from the N-Momentum Phase 3 Pivotal Trial of UPLIZNA

Insider recently sold €3.1m worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Horizon Therapeutics plc Provides Earnings Guidance for the Full Year 2022

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)